logo

For the Inventor, By the Inventor

St. Peter, Germany

Edgar Fritschi

USPTO Granted Patents = 22

Average Co-Inventor Count = 4.2

ph-index = 5

Forward Citations = 121(Granted Patents)


Company Filing History:

goldMedal15 out of 2,538 
 
Warner-lambert Company
 patents
silverMedal6 out of 23 
 
Godecke Aktiengesellschaft
 patents
bronzeMedal1 out of 18 
 
Goedecke Aktiengesellschaft
 patents

Years Active: 1983-1990

Loading Chart...
22 patents (USPTO):Explore Patents
1. 4933368 - N-phenylbenzamide derivatives (1990-06-12),
2. 4857662 - N-phenylbenzamide derivatives (1989-08-15),
3. 4816485 - N-phenylbenzamide derivatives (1989-03-28),
4. 4762837 - 4-alkoxy-pyrido[2,3-d]pyrimidine derivatives for treatment of myocardiac (1988-08-09),
5. 4760081 - 1,6-naphthyridine derivatives useful for treating diseases of the blood (1988-07-26),
6. 4698341 - Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis (1987-10-06),
7. 4681882 - 4-alkoxy-pyrido[2,3-d]pyrimidine derivatives (1987-07-21),
8. 4677108 - 4-oxo-pyrido[2,3-d]pyrimidinone derivatives (1987-06-30),
9. 4626546 - 3-aryl-3-pyrroline derivatives (1986-12-02),
10. 4612311 - 1,2,4-benzothiadiazine oxide derivatives (1986-09-16),
11. 4605673 - 7H-dibenzo(a,c,)cyclohepten-5-one-(7) derivatives (1986-08-12),
12. 4605552 - Calcium-antagonist compositions intended for inhalation and process for (1986-08-12),
13. 4598076 - 2-pyrrolin-3-carbonitril-derivatives, pharmaceutical compositions (1986-07-01),
14. 4587263 - Cycloaliphatic aminosulfonic acid derivatives (1986-05-06),
15. 4584374 - 4-thioxo-benzopyrano[2,3-d]pyrimidine derivatives (1986-04-22),

Title: Edgar Fritschi: Innovator in Pharmaceutical Patents

Edgar Fritschi, located in St. Peter, DE, is an accomplished inventor with a remarkable portfolio of 22 patents. His contributions to the field of pharmaceuticals focus on innovative compounds that aim to address significant medical challenges.

Latest Patents

Fritschi's latest patents revolve around N-phenylbenzamide derivatives. These compounds are described by a general formula I, wherein the radicals R¹, R², and R³ may either be hydrogen atoms or methyl radicals. Notably, these derivatives include pharmacologically acceptable salts that are designed for the control of refractory tumors in mammals. Additionally, his patents illustrate the usage of these derivatives in treating malignant, proliferative, and autoimmune diseases, as well as for immunosuppressive therapy during grafting procedures.

Career Highlights

Throughout his career, Edgar Fritschi has been associated with reputable companies such as Warner-Lambert Company and Godecke Aktiengesellschaft. His work within these organizations has undoubtedly contributed to advancements in pharmaceutical technologies and the development of innovative therapies.

Collaborations

Fritschi has collaborated with notable professionals in his field, including Gerhard Satzinger and Johannes Hartenstein. These collaborations have facilitated the exchange of ideas and have led to the enhancement of research and development in drug innovation.

Conclusion

In conclusion, Edgar Fritschi stands out as a significant figure in the pharmaceutical industry, with a focus on developing groundbreaking treatments through his innovative work on N-phenylbenzamide derivatives. His patent portfolio reflects a dedication to improving health outcomes and addressing critical medical needs.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…